Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

DermTech Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda DermTech için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Biotechs kazanç büyümesi	28.6%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Recent updates

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

May 21

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Mar 02

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

May 10

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

May 06

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jan 16

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Nov 08

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Oct 11

DermTech grants stock options

Oct 11

Diving Into DermTech

Sep 01

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Aug 10

DermTech: Approaching An All Or Nothing Moment

Jun 13

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Jun 04

DermTech - Taking A Second Look At The Growth Thesis

Mar 31

DermTech: Adoption Headwinds And Earnings Misses

Dec 23

Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth

Dec 02

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak DermTech yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

OTCPK:DMTK.Q - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
3/31/2024	16	-90	-72	-72	N/A
12/31/2023	15	-101	-78	-77	N/A
9/30/2023	14	-110	-88	-86	N/A
6/30/2023	14	-120	-94	-91	N/A
3/31/2023	14	-118	-96	-92	N/A
12/31/2022	15	-117	-99	-95	N/A
9/30/2022	15	-115	-99	-97	N/A
6/30/2022	14	-106	-91	-88	N/A
3/31/2022	13	-93	-80	-76	N/A
12/31/2021	12	-78	-65	-62	N/A
9/30/2021	11	-63	-48	-46	N/A
6/30/2021	9	-52	-40	-38	N/A
3/31/2021	7	-45	-34	-32	N/A
12/31/2020	6	-36	-31	-29	N/A
9/30/2020	5	-31	-30	-28	N/A
6/30/2020	5	-27	-28	-26	N/A
3/31/2020	4	-21	-23	-22	N/A
12/31/2019	3	-20	-18	-18	N/A
9/30/2019	2	-18	-13	-13	N/A
6/30/2019	2	-14	-9	-8	N/A
3/31/2019	3	-13	-8	-8	N/A
12/31/2018	2	-10	-8	-8	N/A
12/31/2017	2	-8	N/A	-6	N/A
6/30/2014	0	-6	N/A	-4	N/A
3/31/2014	0	-6	N/A	-3	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: DMTK.Q 'un tahmini kazanç büyümesinin tasarruf oranının ( 2.5% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: DMTK.Q 'un kazançlarının US pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: DMTK.Q şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: DMTK.Q şirketinin gelirinin US pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: DMTK.Q şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: DMTK.Q 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

DermTech Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 26% to US$2.04

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

Consensus EPS estimates upgraded to US$3.11 loss

Consensus revenue estimates fall by 16%

Price target decreased by 22% to US$5.75

Recent updates

DermTech, Inc.(NasdaqCM:DMTK) dropped from NASDAQ Composite Index

Nasdaq to Delist Common Stock of DermTech

Motion for Joint Administration Filed by DermTech, Inc.

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

Kilroy Realty, L.P. Files a Complaint Against DermTech, Inc. for $661,706 in Unpaid Rent

First quarter 2024 earnings released: US$0.58 loss per share (vs US$1.02 loss in 1Q 2023)

Price target decreased by 26% to US$2.04

DermTech Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding Minimum Bid Price Requirement

Consensus revenue estimates decrease by 12%, EPS upgraded

Price target decreased by 11% to US$3.20

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

DermTech, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Dermtech, Inc. Announces Cessation of Claudia Ibarra as Chief Operating Officer

DermTech Announces Positive Topline Results from A Study Evaluating the Dermtech Melanoma Test (Dmt) Across All Skin Types

DermTech, Inc. Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-On Assay

Dermtech Announces Positive Topline Results from Trust 2 Study Evaluating the Dermtech Melanoma Test (Dmt)

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

Pomerantz LLP Announces the Filing of A Class Action Against DermTech, Inc. and Certain Officers

Consensus EPS estimates upgraded to US$3.11 loss

Third quarter 2023 earnings: EPS exceeds analyst expectations

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against DermTech, Inc

DermTech, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Dermtech Appoints Mark Aguillard as Chief Commercial Officer

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

DermTech, Inc. to Report Q2, 2023 Results on Aug 03, 2023

DermTech, Inc. Announces the Todd Wood’s Last Day of Employment as Chief Commercial Officer Will Be July 3, 2023

DermTech, Inc. Announces ECRI Complete Its Evaluation of the Pigmented Lesion Assay

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Consensus revenue estimates fall by 16%

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

DermTech, Inc. Announces Change of CEO

Price target decreased by 22% to US$5.75

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 11% to US$7.00

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

DermTech, Inc. to Report Q4, 2022 Results on Mar 02, 2023

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

DermTech, Inc. Announces the Foundational Assay of Its DermTech Melanoma Test Is Recommended for Coverage by TRICARE

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its Dermtech Melanoma Test (Dmt)

Price target decreased to US$7.33

High number of new directors

DermTech, Inc. Announces Board Committee Appointments

Consensus forecasts updated

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

DermTech, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

DermTech grants stock options

Diving Into DermTech

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

Dermtech, Inc. Provides Revenue Guidance for the Full Year 2022

DermTech, Inc. Appoints Chief Compliance Officer and SVP of Research and Development

DermTech, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Dermtech Announces New Board Appointment

DermTech, Inc.(NasdaqCM:DMTK) dropped from Russell 2000 Dynamic Index

DermTech: Approaching An All Or Nothing Moment

President exercised options to buy US$59k worth of stock.

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

High number of new and inexperienced directors

DermTech, Inc. Presents New Research Differentiating Atopic Dermatitis and Psoriasis At the Society for Investigative Dermatology's Annual Meeting

DermTech, Inc. Affirms Revenue Guidance for the Full-Year 2022

DermTech, Inc., Annual General Meeting, May 26, 2022

DermTech - Taking A Second Look At The Growth Thesis